
Revvity Inc (RVTY) Stock Forecast & Price Target
Revvity Inc (RVTY) Analyst Ratings
Bulls say
Revvity's stock outlook is bolstered by its strategic transition from TST to IGRA testing, which is projected to enhance market growth by several hundred basis points annually. The company benefits from a diversified portfolio that includes a high-growth software solution (Signals) and a strong presence in life sciences and immunodiagnostics, which collectively drive above-market growth and improve overall profitability. As Revvity continues to enhance its competitive position, particularly in the US market through share gains in autoimmune testing, its financial profile is expected to further strengthen due to improved margins and operating efficiencies.
Bears say
Revvity's financial outlook appears negative due to significant challenges in its China market, with total revenues from this region expected to decline to approximately 7% of total revenue by 2025, alongside Immunodiagnostics revenue projected to fall below 5% by 2026. The company faces headwinds from poor economic conditions and cuts to industry funding, which are likely to slow customer demand for its products and services, subsequently impacting growth and market share. Additionally, macroeconomic changes may disrupt Revvity's supply chain, leading to product shortages, inflationary pressures, transit delays, and labor shortages that could hinder operational efficiency and performance.
This aggregate rating is based on analysts' research of Revvity Inc and is not a guaranteed prediction by Public.com or investment advice.
Revvity Inc (RVTY) Analyst Forecast & Price Prediction
Start investing in Revvity Inc (RVTY)
Order type
Buy in
Order amount
Est. shares
0 shares